Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee recommends full approval of Celgene’s Revlimid for myelodysplastic syndromes despite FDA concerns about trial design, dosing and toxicity.
You may also be interested in...
Celgene Revlimid PDUFA Date Extended to January
FDA pushes back the user fee date for Celgene’s myelodysplasic syndromes therapy Revlimid, originally set for Oct. 7, by three months.
Celgene Revlimid PDUFA Date Extended to January
FDA pushes back the user fee date for Celgene’s myelodysplasic syndromes therapy Revlimid, originally set for Oct. 7, by three months.
Revlimid Multiple Myeloma Trial Paused Due to Blood Clots
Celgene asserts that the Mayo Clinic study will resume within weeks, after the trial design is changed to require patients to receive aspirin prior to combo therapy of Revlimid/dexamethasone.